The Office of Management and Budget (OMB) has completed its review of the "Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications," allowing patients continued access to prescribed controlled substances via telehealth without an in-person visit. This temporary extension offers an important reprieve for patients and providers alike as we await a proposed rule for a permanent telemedicine prescribing policy.

This temporary rule extension reflects ongoing discussions as we await a proposed rule for a permanent telemedicine prescribing policy. When this anticipated proposal is released, input from healthcare providers, policy experts, and telehealth advocates will be essential. We encourage all stakeholders to be prepared to share data, insights, and patient stories to help shape the final policy.

What This Means for the Future of Telemedicine Waivers for Controlled Substances

This latest development ensures that patients relying on telehealth for controlled medication access can continue to do so, offering temporary stability for healthcare providers. However, uncertainties remain as the industry awaits a permanent policy. Regulatory agencies, telehealth providers, and patient advocates alike recognize that lasting solutions are necessary for telemedicine prescribing. The anticipated proposed rule is expected to balance patient access and regulatory oversight, with input from healthcare providers, patients, and telehealth advocates central to its shaping.

1. Significance of the Temporary Extension: This extension preserves access to critical telemedicine services for patients requiring controlled medication prescriptions. While it provides temporary stability, it underscores the need for a sustainable, permanent policy solution.

2. Future Pathways for Permanent Policy: The DEA’s forthcoming proposal will likely seek to establish a balanced approach to telemedicine prescribing that considers safety and access. As stakeholders’ perspectives will be essential, input from providers, advocates, and telehealth experts will guide the framework’s development.

3. Next Steps: Stakeholder Actions: Advocacy and public engagement will play a critical role. Stakeholders should be prepared to contribute evidence and insights through public comments, while increasing public awareness of the importance of telemedicine flexibilities for patient care.

4. CTeL’s Role in Shaping Future Policy: CTeL will be actively involved in monitoring and providing updates as the regulatory landscape evolves. CTeL members gain access to real-time policy insights, analysis, and advocacy resources, and can participate in shaping telemedicine’s future through webinars, working groups, and networking opportunities.

Stay Informed and Get Involved with CTeL

For those seeking to remain informed and contribute, CTeL invites engagement through membership. Visit www.ctel.org for regulatory updates or to learn more about the resources and opportunities available to members. Together, with continued advocacy and collaboration, we can work toward a sustainable telehealth policy that benefits patients and providers across the nation.